Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.

@article{Schaeffer2009RenalMC,
  title={Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.},
  author={Edward Schaeffer and Thomas J. Guzzo and Kyle A. Furge and George Netto and Michael Westphal and Karl J. Dykema and Ximing J. Yang and Ming Zhou and Bin Tean Teh and Christian P Pavlovich},
  journal={BJU international},
  year={2009},
  volume={106 1},
  pages={
          62-5
        }
}
STUDY TYPE Aetiology (case series) Level of Evidence 4. OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Renal medullary carcinoma with an ophthalmic metastasis

VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Imaging of Renal Medullary Carcinoma

  • Journal of kidney cancer and VHL
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Management of Atypical Renal Cell Carcinomas

VIEW 1 EXCERPT
CITES BACKGROUND